MOTS-c

Background

Mitochondrial open reading frame of the 12S rRNA type‑c (MOTS‑c) is a 16–amino acid mitochondrial‑derived peptide (MDP) encoded within the MT‑RNR1 (12S rRNA) region of mitochondrial DNA.[3][11][14] MOTS‑c was first characterized in 2015–2016 as part of a family of short bioactive peptides encoded by small open reading frames in mitochondrial rRNA genes, with roles in cellular metabolism and stress responses.[11][14] MOTS‑c is expressed in multiple tissues, detected in plasma, and shows age‑related decline in circulating levels.[3][11][14]

Under metabolic or oxidative stress, MOTS‑c translocates from mitochondria to the nucleus and regulates nuclear gene expression, integrating mitochondrial status with cellular adaptive responses.[3][11][14] Because of its roles in glucose metabolism, insulin sensitivity, inflammation, and cellular stress resistance, MOTS‑c is being investigated as a candidate therapeutic for metabolic disease, cardiovascular disease, aging‑related conditions, and pain.[3][11][14]

As of the latest published literature, MOTS‑c remains an experimental peptide; there are no approved MOTS‑c–based drugs, and its use is confined to preclinical research and limited exploratory human studies.[3][11][14]

Mechanism of action

Origin and cellular localization

MOTS‑c is translated from a small open reading frame in the mitochondrial 12S rRNA gene, exported to the cytosol and extracellular space, and can enter the nucleus during stress.[3][11][14] Nuclear translocation enables MOTS‑c to modulate transcriptional programs that support metabolic homeostasis and stress resistance.[3][11][14]

Metabolic signaling and AMPK pathway

Key mechanistic features include:

• Targeting the folate cycle and one‑carbon metabolism: MOTS‑c inhibits steps in the folate cycle, leading to accumulation of 5‑aminoimidazole‑4‑carboxamide ribonucleotide (AICAR), an endogenous AMP mimetic.[7][11]
• Activation of AMP‑activated protein kinase (AMPK): Elevated AICAR activates AMPK, a central energy sensor that promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.[7][11]
• Upregulation of PGC‑1α and mitochondrial biogenesis: Through AMPK, MOTS‑c increases expression of peroxisome proliferator‑activated receptor‑γ coactivator‑1α (PGC‑1α), enhancing mitochondrial biogenesis and oxidative capacity.[7][11] In skeletal muscle of high‑fat diet (HFD) mice, MOTS‑c and exercise synergistically increased AMPK phosphorylation, PGC‑1α, and GLUT4, with improved insulin sensitivity.[7]

Nuclear gene regulation and stress response

Upon nuclear translocation under metabolic stress, MOTS‑c binds to chromatin and regulates stress‑response and metabolic genes, promoting cellular adaptation, antioxidant responses, and proteostasis.[3][11][14] This “mitochondria‑to‑nucleus” retrograde signaling links mitochondrial function to systemic metabolic regulation.

Tissue‑specific mechanisms

Recent studies describe additional mechanisms in specific tissues:

• Reproductive system: MOTS‑c preserves spermatogenesis in mouse microgravity and oxidative stress models by upregulating SLC7A11, limiting lipid peroxidation and suppressing ferroptosis.[2]
• Cardiovascular system: In pressure overload–induced heart failure and neonatal hyperoxia cardiotoxicity, MOTS‑c activates AMPK, reduces oxidative stress, and inhibits cell death programs including oxeiptosis via maintaining KEAP1–PGAM5 interaction.[8][12]
• Immune and antiviral signaling: In chronic hepatitis B virus (HBV) infection, MOTS‑c modulates mitochondrial remodeling and cytoskeletal proteins (e.g., MYH9, actin), contributing to suppressed HBV replication and improved mitochondrial function.[5]
• Membrane repair: MOTS‑c facilitates plasma membrane repair by promoting translocation of TRIM72 (MG53) to injury sites, aided by interaction with plasma membrane lipids, thereby enhancing sarcolemmal integrity after mechanical stress.[13]
• Pain modulation: In neuropathic and inflammatory pain, MOTS‑c activates AMPK in the spinal cord, inhibits microglial activation, reduces pro‑inflammatory cytokines, and limits neuronal oxidative damage.[10][15]

Specific high‑affinity cell surface receptor(s) for MOTS‑c have not been definitively identified as of current literature; most mechanistic work emphasizes intracellular metabolic and signaling pathways (folate cycle, AMPK, KEAP1–PGAM5, MAPK/ERK–NF‑κB).[3][7][8][11]

Evidence summary

Human observational and small clinical data

Human data remain limited and largely observational or biomarker‑focused:

• Aging and metabolic status: Circulating MOTS‑c levels decline with age and are associated with metabolic health markers in cross‑sectional cohorts, suggesting a role as a biomarker of mitochondrial health and aging.[11][14]
• Aortic valve disease: In a cross‑sectional study of 17 patients with aortic valve disease (AVD) undergoing aortic valve replacement and 22 healthy controls, plasma MOTS‑c levels measured by ELISA were significantly lower in AVD patients, independent of age and sex, supporting mitochondrial dysfunction in AVD and potential biomarker utility.[1]
• HBV infection: In a cohort of 404 patients with HBV infection and 85 healthy controls, MOTS‑c levels were inversely correlated with HBV DNA (R = −0.71), and receiver operating characteristic analysis showed high diagnostic performance for differentiating chronic hepatitis B from healthy controls (AUC 0.953) and immune‑active from inactive carrier states (AUC 0.869).[5] MOTS‑c levels also tracked clinical subgroups and treatment response in 20 clinical treatment cohorts.[5]

As of current publications, controlled interventional trials administering exogenous MOTS‑c to humans are not well documented; available data are primarily preclinical or mechanistic, with some early phase or pilot work not yet widely published.

Metabolic disease and obesity (preclinical)

Multiple rodent studies demonstrate improved glucose tolerance, insulin sensitivity, and weight control with MOTS‑c administration in diet‑induced obesity and insulin resistance, mediated via AMPK activation and enhanced skeletal muscle glucose uptake.[7][11][14] In HFD mice, MOTS‑c, alone or with exercise, improved glucose metabolism, reduced insulin resistance, and restored muscle MOTS‑c, PGC‑1α, and GLUT4 levels.[7]

Cardiovascular models

• Pressure overload heart failure: In a transverse aortic constriction (TAC) mouse model, MOTS‑c overexpression or peptide administration preserved left ventricular function, reduced hypertrophy and fibrosis, and decreased cardiomyocyte apoptosis; effects were associated with AMPK activation and reduced oxidative stress.[12]
• Neonatal hyperoxia cardiotoxicity: In neonatal mice exposed to 85% oxygen, MOTS‑c treatment ameliorated cardiac hypertrophy, fibrosis, and dysfunction, with evidence for inhibition of KEAP1–PGAM5–AIFM1–mediated oxeiptosis.[8]

HBV infection and antiviral effects

In HBV‑infected cell and mouse models, exogenous MOTS‑c reduced HBV replication by ~50–70%, improved liver function, and promoted mitochondrial remodeling without evident toxicity.[5] Mechanistically, MOTS‑c interacted with cytoskeletal and mitochondrial proteins (e.g., MYH9) and enhanced antiviral signaling.[5]

Pain and neurological models

• Neuropathic pain: In spared nerve injury (SNI) mice, MOTS‑c levels were reduced in plasma and spinal dorsal horn.[10] Intrathecal MOTS‑c produced dose‑dependent antinociceptive effects, blocked by AMPK inhibitor dorsomorphin but not by naloxone, indicating an AMPK‑dependent, non‑opioid mechanism.[10] MOTS‑c reduced spinal microglial activation and pro‑inflammatory cytokine expression and suppressed neuronal oxidative damage.[10]
• Cancer‑induced bone pain: In a mouse model of bone cancer pain, intraperitoneal MOTS‑c significantly reduced mechanical allodynia and bone destruction, with increased AMPK‑mediated mitochondrial biogenesis in spinal cord neurons and glia.[15]
• Inflammatory pain: In multiple mouse models (formalin, capsaicin, λ‑carrageenan, CFA), central or systemic MOTS‑c administration attenuated acute and chronic inflammatory pain, reduced central and peripheral inflammatory mediators, and modulated glial activation.[9]

Other preclinical domains

• Membrane repair and muscle function: In human exercise cohorts and mouse models, MOTS‑c levels correlated with TRIM72 abundance and membrane repair capacity, and exogenous MOTS‑c improved sarcolemmal integrity after eccentric contraction, enhancing functional recovery.[13]
• Ischemic tissue flaps: In rodent soft tissue ischemia models, MOTS‑c improved flap survival, blood flow, angiogenesis, and collagen remodeling while reducing lysosomal membrane permeabilization, pyroptosis, and inflammation via a PLA2G4A–MAPK1/3–NF‑κB pathway.[6]
• Male fertility: In mouse spermatogenesis models under simulated microgravity, MOTS‑c restored sperm counts, seminiferous tubule architecture, and spermatogonia proliferation by upregulating SLC7A11 and inhibiting ferroptosis.[2]

Overall, evidence is predominantly preclinical, with mechanistic breadth but limited translation to human therapeutic trials.

Clinical and research uses

Approved indications

• There are no approved therapeutic indications for MOTS‑c in the United States, European Union, or other major regulatory jurisdictions.[3][11][14]

Investigational and proposed uses (experimental)

Based on preclinical data and human observational studies, MOTS‑c is being investigated as a candidate for:

• Metabolic disorders: obesity, insulin resistance, and type 2 diabetes, via enhanced AMPK signaling and improved skeletal muscle glucose uptake.[7][11][14]
• Cardiovascular disease: pressure overload–induced heart failure and hyperoxia‑related neonatal cardiomyopathy, through anti‑oxidative, anti‑apoptotic, and anti‑oxeiptotic actions.[8][12]
• Chronic hepatitis B: as an adjunct antiviral and biomarker for disease activity and treatment response.[5]
• Pain conditions: neuropathic pain, inflammatory pain, and cancer‑induced bone pain, by modulating spinal AMPK, neuroinflammation, and mitochondrial function.[9][10][15]
• Male infertility associated with impaired spermatogenesis and oxidative stress.[2]
• Aging and sarcopenia, due to age‑related decline in MOTS‑c and roles in mitochondrial biogenesis and membrane repair.[11][13][14]

Use of MOTS‑c outside formal research settings would be considered off‑label and investigational, with unproven safety and efficacy.

Dosing context

Published dosing information is preclinical and should not be extrapolated to humans without formal dose‑finding studies.

• Rodent systemic dosing: Many mouse studies employ intraperitoneal MOTS‑c doses in the range of approximately 5–25 mg/kg, administered once daily or several times per week over periods from days to weeks, depending on the model (e.g., metabolic, cardiac, pain).[7][10][12][15] Exact regimens vary by study and disease model.
• Intrathecal / central dosing: Neuropathic and inflammatory pain studies use intrathecal MOTS‑c microgram‑scale doses in mice to achieve local spinal cord exposure, demonstrating AMPK‑dependent antinociception.[9][10]
• Ex vivo / in vitro: Cell culture experiments typically use MOTS‑c at nanomolar to micromolar concentrations to assess metabolic, antioxidant, or signaling effects.[7][8][11]

There are no validated human therapeutic dosing regimens, and any clinical dosing remains investigational. Doses reported in non‑peer‑reviewed or commercial sources are not substantiated by regulatory‑grade data and are not considered here.

Safety profile

Preclinical safety observations

Across multiple rodent and cell studies, MOTS‑c has generally been well tolerated at experimental doses, with no major organ toxicity or mortality reported over the time frames studied.[5][7][8][10][12][15] In HBV models, MOTS‑c reduced viral replication and improved liver function without notable toxicity in assessed parameters.[5]

Potentially beneficial safety‑related features include:

• Reduction of oxidative stress and protection against programmed cell death (apoptosis, oxeiptosis, ferroptosis) in heart, testis, and neuronal tissue.[2][8][12]
• Improved mitochondrial function and membrane repair, which might mitigate tissue injury in ischemia or mechanical stress.[6][13]

Unknowns and limitations

• Lack of long‑term toxicology: Chronic exposure, carcinogenicity, reproductive toxicity, and immunogenicity have not been systematically evaluated.
• Immunogenic potential: As a peptide therapeutic, MOTS‑c could induce anti‑drug antibodies, but this has not been well studied.
• Off‑target metabolic effects: Sustained AMPK activation and folate cycle modulation could have unanticipated effects on cell growth, nucleotide synthesis, or interacting pathways, especially in cancer or proliferative diseases.[3][11]

Given these gaps, any clinical use should be restricted to controlled research settings with appropriate monitoring.

Adverse effects (reported or theoretical)

Specific, recurrent adverse events in humans have not been characterized due to lack of interventional trials. In animal studies, overt toxicity is generally not observed; however, the following are theoretical or mechanistic concerns:

• Altered energy metabolism and potential hypoglycemia risk in susceptible settings due to AMPK activation.
• Modulation of immune and inflammatory pathways, with uncertain effects in autoimmunity or infection.[3][5][11]
• Possible mitochondrial–nuclear communication disruption if supraphysiologic doses alter stress response pathways chronically.[11][14]

Regulatory status

• United States (FDA): MOTS‑c is not approved as a drug, biologic, or dietary ingredient by the U.S. Food and Drug Administration. It is not listed among FDA‑approved peptide therapeutics, and no FDA labeling exists as of current literature.[3][11][14]
• European Union (EMA): MOTS‑c is not authorized as a medicinal product by the European Medicines Agency. No centralized or national marketing authorizations are documented.[3][11][14]
• Clinical trials: As of the latest published reviews, MOTS‑c is described as a promising but preclinical mitochondrial‑derived peptide with no established therapeutic application, and registered interventional trials involving exogenous MOTS‑c are limited or absent in major registries.[3][11][14]

Accordingly, any use of MOTS‑c in humans should be considered experimental, ideally under institutional review board oversight and in compliance with applicable regulations for investigational medicinal products.